UNITED STATES SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                   FORM 12b-25
                                                             SEC FILE NUMBER
                           NOTIFICATION OF LATE FILING          001-10304

                                   FORM 10-KSB                CUSIP NUMBER

                       For Period Ended: December 31, 2004

[Nothing in this form shall be construed to imply that the Commission has
verified any information contained herein.]

PART I - REGISTRANT INFORMATION


                              AMEXDRUG CORPORATION
                     8909 West Olympic Boulevard, Suite 208
                         Beverly Hills, California 90211

PART II - RULES 12b-25(b) AND (c)

     If the subject report could not be filed without unreasonable effort or
expense and the Registrant seeks relief pursuant to Rule 12b-25(b), the
following should be completed. (Check box if appropriate)

 [X]           (a) The reasons described in reasonable detail in Part III of
          this form could not be eliminated without unreasonable effort or
          expense;

 [X]           (b) The subject annual report, semi-annual report, transition
          report on Form 10-K, Form 20-F, 11-K, Form N-SAR, or portion thereof,
          will be filed on or before the fifteenth calendar day following the
          prescribed due date; or the subject quarterly report or transition
          report on Form 10-Q, or portion thereof will be filed on or before the
          fifth calendar day following the prescribed due date; and

 [X]           (c) The accountant's statement or other exhibit required by Rule
          12b-25 has been attached if applicable.



PART III - NARRATIVE

     State below in reasonable detail the reasons why the Form 10-K, 11-K, 10-Q,
N-SAR, or the transition report or portion thereof, could not be filed within
the prescribed time period.

     The Company is awaiting the completion of the audit of its financial
statements and a few additional days are needed to complete and finalize the
report.

PART IV - OTHER INFORMATION

          (1) Name and telephone number of person to contact in regard to this
     notification.

                  Jack Amin         310/855-0475





          (2) Have all other periodic reports required under Section 13 or 15(d)
     of the Securities Exchange Act of 1934 or Section 30 of the Investment
     Company Act of 1940 during the preceding 12 months (or for such shorter)
     period that the Registrant was required to file such reports) been filed?
     If answer is no, identify report(s). [X] Yes [ ] No

          (3) Is it anticipated that any significant change in results of
     operations from the corresponding period for the last fiscal year will be
     reflected by the earnings statements to be included in the subject report
     or portion thereof? [ ]Yes  [X] No




                              AMEXDRUG CORPORATION

has caused this notification to be signed on its behalf by the
undersigned hereunto duly authorized.

                                            AMEXDRUG CORPORATION

                                            By: /s/  Jack Amin
                                                ---------------

                                            Jack Amin, President

Date: March 29, 2005

[ATTENTION: Intentional misstatements or omissions of fact constitute Federal
Criminal Violations (See 18 U.S.C. 1001).]